Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis
JAMA Cardiology, 9 ottobre 2024

2) Hepatic T1 Mapping as a Novel Cardio-Hepatic Axis Imaging Biomarker Early after STEMI
European Heart Journal Cardiovascular Imaging, 4 ottobre 2024

3) Myocardial Infarction and Pulmonary Embolism: Causal or Temporal Association?
JACC: Case Reports, 18 settembre 2024

4) Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk
Canadian Journal of Cardiology, 1 febbraio 2024

5) Acute Response of the Noninfarcted Myocardium and Surrounding Tissue Assessed by T2 Mapping After STEMI
JACC Cardiovascular Imaging, 24 gennaio 2024

6) Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study
International Journal of Cardiology _ Heart & Vasculature, 23 gennaio 2024

7) Coronary embolisation of native aortic valve debris during transcatheter aortic valve replacement: mechanical embolectomy and histopathological analysis
The Lancet, 13 gennaio 2024

8) One- Versus Three-Month DAPT in Older Patients at High Bleeding Risk Undergoing PCI: Insights From the XIENCE Short DAPT Global Program
American Journal of Cardiology, 5 gennaio 2024

9) Antithrombotic Therapy in Patients with Acute Coronary Syndrome: Similarities and Differences between a European Expert Consensus Document and the 2023 European Society of Cardiology Guidelines
European Heart Journal • Acute Cardiovascular Care, 3 gennaio 2024

10) Reply: Unconvinced by Data or Resistance to Change?
Journal of the American College of Cardiology, 2 gennaio 2024

11) Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiology, 22 novembre 2023

12) One or 3 months dual antiplatelet therapy in high bleeding risk patients: splitting hair or aiming at the bullseye?
European Heart Journal, 20 novembre 2023

13) Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI
EuroIntervention, 21 agosto 2023

14) Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
Circulation, 20 giugno 2023

15) P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention, 12 giugno 2023

16) Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis
JACC Cardivascular Interventions, 12 giugno 2023

17) Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the ...
Journal of Cardiovascular Translational Research, 1 giugno 2023

18) [Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease]
Giornale italiano di Cardiologia, aprile 2023

19) Antithrombotic therapy in patients with established atherosclerotic coronary disease
Heart, 4 maggio 2023

20) Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease: 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) ...
European Heart Journal of Cardiovascular Pharmacotherapy, 29 aprile 2023

21) Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome
Canadian Journal of Cardiology, 26 aprile 2023

22) Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight
International Journal of Cardiology, 18 aprile 2023

23) De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options
European Journal of Internal Medicine, aprile 2023

24) Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the ...
European Heart Journal. Cardiovascular Pharmacotherapy, 10 aprile 2023

25) Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial
JACC Cardiovascular Interventions, 10 aprile 2023

26) European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases
European Journal of Vascular And Endovascular Surgery, 3 aprile 2023

27) P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
Journal of The American College of Cardiology, 14 febbraio 2023

28) Acute Coronary Occlusion in Patients With Non-ST-Segment Elevation Out-of-Hospital Cardiac Arrest
Journal of The American College of Cardiology, 7 febbraio 2023

29) Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome
JACC Cardiovascular Interventions, 23 gennaio 2023

30) Reply: Distal Transradial Access in Acute Coronary SyndromesShould We Give the First Try?
JACC Cardiovascular Interventions, 23 gennaio 2023

31) EnVast Mechanical Thrombectomy After Thrombus Aspiration Failure in a STEMI With a Massive Thrombotic Burden
JACC Cardiovascular Interventions, 9 gennaio 2023

32) Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry
EuroIntervention, 13 dicembre 2022

33) Sailing in the complexity of the ’shark-fin’ sign
Heart, 13 dicembre 2022

34) Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
European Heart Journal, 7 dicembre 2022

35) Distal vs Conventional Radial Access for Coronary Angiography and/or Intervention: A Meta-Analysis of Randomized Trials
JACC Cardiovascular Interventions, 28 novembre 2022

36) Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials
European Heart Journal Cadiovascular Pharmacotherapy, 25 novembre 2022

37) Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial
Journal of the American Heart Association, 17 maggio 2022

38) Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial
EuroIntervention, 9 marzo 2022

39) Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study
Europace, 7 marzo 2022

40) Not only lungs: COVID-19 hits platelets as well
European Heart Journal, 18 febbraio 2022

41) Left atrial adaptation in ischemic heart disease: insights from a cardiovascular magnetic resonance study
The International Journal of Cardiovascular Imaging, 17 febbraio 2022

42) Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification
PLos One, 16 febbraio 2022

43) Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter?
Journal of the American College of Cardiology, 8 febbraio 2022

44) Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
The New England Journal of Medicine, 28 ottobre 2021

45) Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
Circulation, 12 ottobre 2021

46) 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
JACC: Cardiovascular Interventions, 13 settembre 2021

47) Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial
European Heart Journal - Acute Cadiovascular Care, 7 settembre 2021

48) Selatogrel and other P2Y12 inhibitors’ putative off-target effects
Journal of Cardiovascular Pharmacology, 31 agosto 2021

49) Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, 30 agosto 2021

50) Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
The New England Journal of Medicine, 28 agosto 2021

51) Intimal Flap Sealing and Healing of Spontaneous Coronary Artery Dissection With Drug-Eluting Balloons
JACC: Cardiovascular Interventions, 23 agosto 2021

52) Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study
JACC: Cardiovascular Interventions, 23 agosto 2021

53) Bleeding avoidance strategies in percutaneous coronary intervention
Nature Reviews Cardiology, 23 agosto 2021

54) Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care?
EuroIntervention, 6 agosto 2021

55) Management of acute coronary syndromes in older adults
European Heart Journal, 4 agosto 2021

56) P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
BMJ, 16 giugno 2021

57) Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria
Journal of the American Heart Association, 15 giugno 2021

58) Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry
Circulation - Cardiovascular Interventions, maggio 2021

59) From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain
European Heart Journal - Cardiovascular Imaging, 13 maggio 2021

60) Large-Bore Radial Access for Complex PCI: A Flash of COLOR With Some Shades of Grey
JACC: Cardiovascular Interventions, 7 maggio 2021

61) Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure
Journal of Cardiovascular Translational Research, 21 aprile 2021

62) Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial"
Circulation, 30 marzo 2021

63) Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management
JACC: Cardiovascular Interventions, 22 febbraio 2021

64) Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis
JACC: Cardiovascular Interventions, 22 febbraio 2021

65) Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY
Circulation: Cardiovascular Quality and Outcomes, 4 febbraio 2021

66) Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes
Journal of the American College of Cardiology, 2 febbraio 2021

67) Patient-tailored antithrombotic therapy following percutaneous coronary intervention
European Heart Journal, 29 gennaio 2021

68) Validation and additive predictive value of the Academic Research Consortium-High Bleeding Risk Criteria in Older Adults
Thrombosis and Haemostasis, 22 dicembre 2020

69) The multiplication of loaves and fishes approach: A Critic to Double anti-thrombotics or to Double number of ischemic events?
European Heart Journal Cardiovascular Pharmacotherapy, 19 dicembre 2020

70) Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy
European Journal of Heart Failure, 1 novembre 2020

71) The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury
European Heart Journal: Acute Cardiovascular Care, https://journals.sagepub.com/doi/10.1177/2048872620934298

72) Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk
European Heart Journal, https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehaa671/5919236?redirectedFrom=fulltext

73) Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation
Catheterization & Cardiovascular Interventions, https://onlinelibrary.wiley.com/doi/10.1002/ccd.29318

74) Design and Rationale of the XIENCE Short DAPT Clinical Program: an Assessment of the Safety of 3-month or 1-month DAPT in Patients at High Bleeding Risk Undergoing PCI with an Everolimus-Eluting Stent
American Heart Journal, https://www.sciencedirect.com/science/article/abs/pii/S0002870320302751?via%3Dihub

75) PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY
European Heart Journal - Cardiovascular Pharmacotherapy, https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvaa106/5907912?redirectedFrom=fulltext
Marco Valgimigli
is currently collaborating with
Istituto Cardiocentro Ticino (ICCT) (Rif. ICCT)
Via Tesserete 48
6900 Lugano
Marco Valgimigli
on behalf of
Istituto Cardiocentro Ticino (ICCT) EOC (Rif. ICCT)
is currently participating in the Research Group
Ricerca Cardiovascolare
as Group Leader [Rif. 55110]
Marco Valgimigli
on behalf of
Istituto Cardiocentro Ticino (ICCT) EOC (Rif. ICCT)
is currently Research Program Leader [Rif. 50110] for
Ricerca Clinica (Rif. 10000 2023)